Welcome to our dedicated page for Pfizer SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pfizer Inc. (PFE) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, with AI‑powered tools to help interpret complex documents. As a large issuer in the pharmaceutical preparation manufacturing industry, Pfizer files a wide range of reports that are important for understanding its operations, capital structure and risk profile.
Investors can review Form 8‑K current reports that describe material events such as financial results, public offerings of notes, acquisitions and guidance updates. Recent 8‑K filings detail second‑ and third‑quarter 2025 financial results, full‑year 2025 and 2026 revenue and adjusted EPS guidance, a multi‑tranche public offering of senior notes with maturities extending to 2065, and the completed acquisition of Metsera, a company developing GLP‑1‑based obesity therapies.
Pfizer’s 8‑Ks also reference shelf registration statements and supplemental indentures governing its debt securities, as well as underwriting and pricing agreements with major investment banks. These filings help users track how Pfizer raises long‑term capital and manages its balance sheet. Other 8‑Ks furnish press releases under Regulation FD, including guidance updates that outline expected revenue contributions from COVID‑19 products and the impact of loss of exclusivity on certain medicines.
On Stock Titan, AI‑generated summaries highlight the key points of lengthy filings, explaining in plain language what new debt offerings, acquisitions, guidance changes or other events may mean for the company. Users can quickly identify which exhibits relate to indentures, legal opinions or merger agreements, and can follow how Pfizer’s financing activities and strategic transactions evolve over time.
In addition to 8‑Ks, this page links to Pfizer’s other core SEC reports, such as annual and quarterly filings, where available. Together, these documents provide a regulatory record of Pfizer’s financial performance, risk factors, capital markets activity and major corporate actions, with AI assistance to make the information more accessible.
Gottlieb Scott reported acquisition or exercise transactions in this Form 4 filing.
Pfizer director Scott Gottlieb received a new grant of phantom stock units as part of his board compensation. On this Form 4, he was awarded 7,686.539 phantom stock units tied to Pfizer common stock at a reference value of $26.67 per unit, bringing his total phantom stock holdings to 57,001.814 units.
According to the footnotes, each unit represents one phantom share of common stock and was granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. These units represent deferred director compensation that will be settled in cash or common stock, at his election, after he retires from the Board of Directors, making this a non‑market, compensation-related transaction.
NORA JOHNSON SUZANNE M reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Suzanne M. Nora Johnson received a grant of 7,686.539 Phantom Stock Units on April 23, 2026. Each unit represents one phantom share of Pfizer common stock and was granted at a reference price of $26.67 per unit as deferred director compensation. Following this award, her balance in these units increased to 116,982.649. The units will be settled in cash or common stock, at her election, after she retires from the Board.
LITTMAN DAN R. reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Dan R. Littman received an award of 7,686.539 Phantom Stock Units on deferred compensation terms. Each unit represents one phantom share of Pfizer common stock and is tied to a reference price of $26.67 per unit.
After this grant, Littman holds a total of 74,533.568 Phantom Stock Units. The units represent deferred director compensation under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors and will be settled in cash or common stock, at his election, after he retires from the Board.
BLAYLOCK RONALD E reported acquisition or exercise transactions in this Form 4 filing.
Pfizer director Ronald E. Blaylock received a grant of 7,686.539 Phantom Stock Units linked to Pfizer common stock. The units, valued using a reference price of $26.67 per unit, increase his total phantom stock holdings to 84,012.660 units. Each unit represents one phantom share and was granted under Pfizer’s Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. This award represents deferred director compensation that will be settled in cash or common stock, at his election, after he retires from the Board.
Buckley Mortimer J reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Mortimer J. Buckley received a grant of phantom stock units as part of his deferred compensation. On this Form 4, he was awarded 7,686.539 phantom stock units tied to Pfizer common stock, bringing his total phantom units to 24,391.124 held directly.
Each unit represents one phantom share of common stock and was granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. These units reflect deferred director compensation and will be settled in cash or Pfizer common stock, at the director’s election, after he retires from the Board of Directors.
Desmond-Hellmann Susan reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Susan Desmond-Hellmann received a grant of phantom stock units as part of her deferred board compensation. On this Form 4, she was awarded 7,686.539 phantom stock units, each linked to one share of Pfizer common stock. Following the award, she holds 45,635.605 phantom stock units in total. These units are granted under Pfizer’s Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors and will be settled in cash or common stock, at her election, after she retires from the board.
Echevarria Joseph reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Joseph Echevarria received a grant of 7,686.539 Phantom Stock Units tied to common stock. The units were awarded as director compensation under Pfizer’s Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors and bring his reported phantom unit balance to 161,084.684. Each unit represents one phantom share and will be settled in cash or common stock, at his election, after he retires from the board.
Pfizer Inc. director Shantanu Narayen received a grant of 7,686.539 Phantom Stock Units on common stock-equivalent terms. The award was made at a reference value of $26.67 per unit and is classified as a grant or award acquisition rather than an open-market purchase.
Following this grant, Narayen holds a total of 195,611.680 Phantom Stock Units directly. Each unit represents one phantom share of Pfizer common stock and was granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. These units reflect deferred director compensation that will be settled in cash or common stock, at Narayen’s election, after his retirement from the Board.
PFIZER INC Executive Vice President Dennis P. Hancock filed an amended Form 3 to correct his initial insider holdings report. The amendment adds 1,940 shares of common stock held indirectly through the Pfizer Savings Plan under a Rule 16b-3 plan that were previously omitted.
Quincey James reported acquisition or exercise transactions in this Form 4 filing.
PFIZER INC director James Quincey reported a compensation grant of phantom stock units tied to Pfizer common stock. He received 7,686.539 phantom stock units on the reported date at a reference value of $26.67 per unit.
Each unit represents one phantom share of common stock and was granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. These units reflect deferred director compensation and will be settled in cash or common stock, at Quincey’s election, after he retires from the Board. Following this award, his balance under this plan increased to 85,004.077 phantom stock units.